Gilead gets new CEO, FDA poaches number two from Flatiron Health

Gilead gets new CEO; FDA poaches number two from Flatiron Health

By PharmaCompass

2018-12-20

Impressions: 119 Article

There were some high level appointments in the world of pharmaceuticals. Incidentally, both the picks were from Roche.

First, Gilead Sciences Inc announced Daniel O’Day to be its chairman and CEO, effective March 1, 2019. O’Day will replace John Martin as chairman and John Milligan as CEO.

From January 1, chief patient officer Gregg Alton will serve as interim CEO, until O’Day takes over.

O’Day has been with Roche for 30 years, and has been the CEO of Roche Pharmaceuticals since 2012, where he has overseen R&D and commercialization of products across the pharma’s core areas of cancer, neuroscience, infectious disease, immunology, ophthalmology and respiratory disease.

Second, the US Food and Drug Administration (FDA) named Amy Abernethy, currently the chief medical officer at Flatiron Health, a unit of Roche, as its new principal deputy commissioner of food and drugs. Abernethy, an oncologist, will succeed Rachel Sherman, who is retiring from the FDA.

The role is one of the FDA’s highest-ranking positions, second only to commissioner Scott Gottlieb. Abernethy will be a key adviser.

Flatiron Health is a medical-technology firm that uses its data to help doctors and hospitals treat cancer patients. Flatiron was purchased by Roche at a valuation of US$ 2.1 billion earlier this year. Before joining Flatiron, Abernethy was a professor at the Duke University School of Medicine.

The PharmaCompass Newsletter – Sign Up, Stay Ahead

Feedback, help us to improve. Click here

Image Credit : #Phisper Infographic by SCORR MARKETING & PharmaCompass is licensed under CC BY 2.0

“ The article is based on the information available in public and which the author believes to be true. The author is not disseminating any information, which the author believes or knows, is confidential or in conflict with the privacy of any person. The views expressed or information supplied through this article is mere opinion and observation of the author. The author does not intend to defame, insult or, cause loss or damage to anyone, in any manner, through this article.”

NEWS

DRUGS & DEVELOPMENTS

MARKET INTEL by PharmaCompass